Abstract: A system for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound, which system includes a dry powder inhaler device containing a powder containing the pharmaceutically active compound, wherein (a) of the powder particles dispensed by the inhaler device (the “metered DPI dose”), at least 40% are less than about 10 microns in diameter at the point the particles exit the inhaler, (b) the metered DPI dose is sufficient to produce a clinically effective result in a patient; and (c) the amount of the compound in the metered DPI dose is not more than 70% of the minimal amount of the compound which, when dispensed in a pressurized metered dose inhaler, produces an equivalent clinically effective result in the same patient.

Abstract: A system for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound, which system includes a dry powder inhaler device containing a powder containing the pharmaceutically active compound, wherein (a) of the powder particles dispensed by the inhaler device (the “metered DPI dose”), at least 40% are less than about 10 microns in diameter at the point the particles exit the inhaler, (b) the metered DPI dose is sufficient to produce a clinically effective result in a patient; and (c) the amount of the compound in the metered DPI dose is not more than 70% of the minimal amount of the compound which, when dispensed in a pressurized metered dose inhaler, produces an equivalent clinically effective result in the same patient.

Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.

Abstract: A system for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound, which system includes a dry powder inhaler device containing a powder containing the pharmaceutically active compound, wherein(a) of the powder particles dispensed by the inhaler device (the "metered DPI dose"), at least 40% are less than about 10 microns in diameter at the point the particles exit the inhaler,(b) the metered DPI dose is sufficient to produce a clinically effective result in a patient; and(c) the amount of the compound in the metered DPI dose is not more than 70% of the minimal amount of the compound which, when dispensed in a pressurized metered dose inhaler, produces an equivalent clinically effective result in the same patient.

Abstract: Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.

Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.

Abstract: A method is provided for dispensing a clinically effective dose of an inhalable, pharmaceutically active compound. The method includes providing a dry powder inhaler containing a powder including the pharmaceutically active compound, and administering to a patient a dose of the compound that is less than 70% of the dose that would be necessary to obtain a physiologically equivalent result were the compound administered by a pressurized metered dose inhaler. The pharmaceutically active compound is in the form of primary particles at least 80% of which have a particle size of less than 10 microns, and the primary particles are provided as agglomerates which are deagglomerated during inhalation so that at least 40% of the dose administered is in the form of primary particles.

Abstract: The invention relates to disposable devices for introducing substances into body cavities of a patient. The device comprises a container for holding a substance which is connected to a tube ending in an opening which is inserted into a body cavity. The opening is sealed by a frangible seal located inside the opening. An actuating rod ruptures and removes the seal upon actuation. The actuating rod is provided with supporting rods extending to the container which are connected to the container by frangible connections. The supporting rod serves as a safe-guard against accidental rupture of the seal and as a guide for a controlled movement of said the actuating rod. The supporting rod also defines and protects an area to be kept sterile. The invention also relates to a moulding apparatus and to a method for making said device.

Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.

Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.